×

Macrocure Ltd. to Participate in Upcoming Symposium on Advanced Wound Care

PETACH TIKVA, Israel, April 13, 2015 (GLOBE NEWSWIRE) -- Macrocure Ltd. (Nasdaq:MCUR), a clinical-stage biotechnology company focused on developing a novel therapeutic platform to address chronic and hard-to-heal wounds, today announced that it will participate in the upcoming Symposium on Advanced Wound Care from April 29 – May 3, 2015 in San Antonio, Texas.

Symposium on Advanced Wound Care (SAWC)
Website: http://www.sawc.net/spring/

Lunch Symposium Supported by Macrocure:

  • Title: CureXcell®: The Next Generation of Advanced Living Cell-Based Therapy in Wound Healing
  • Date: Thursday, April 30, 2015
  • Time: 12:30 pm – 2:00 pm
  • Venue: Henry B. Gonzalez Convention Gonzalez Convention Center, San Antonio, TX
  • Presenter(s): Robert Kirsner, MD, PhD and William W. Li, MD

Poster Presentation:

  • Title: BIOLOGICAL PROPERTIES OF A LIVING HUMAN ACTIVATED LEUKOCYTE SUSPENSION (LHALS) AND ITS ASSOCIATION WITH WOUND HEALING AND TISSUE REMODELING
  • Number: P.ET04
  • Author(s): P. Naumenko1, V. Shah1, W. W. Li2, M. Molyneaux1, A. Zuloff-Shani1 ; 1Macrocure, Ltd., Research & Development, Tenafly, NJ, USA; 2The Angiogenesis Foundation, Cambridge, MA, USA
  • Date: Friday, May 1, 2015
  • Time: 7:15 pm – 8:30 pm at Poster Gala/Awards Session
  • Venue: Henry B. Gonzalez Convention Gonzalez Convention Center, San Antonio, TX

Oral Abstract:

  • Title: WOUND HEALING ACCELERATION BY LIVING HUMAN ACTIVATED LEUKOCYTE SUSPENSION (LHALS) IN A SPLINTED FULL-THICKNESS DERMAL WOUND MODEL IN ATHYMIC RATS
  • Number: N1.04
  • Author(s): V. R. Shah1, A. Zuloff-Shani1, W. W. Li2, M. Molyneaux1 ; 1Macrocure, Ltd., Research & Development, Tenafly, NJ, USA; 2The Angiogenesis Foundation, Cambridge, MA, USA
  • Moderators: Timothy Koh, PhD; Kara Spiller, PhD
  • Date: Saturday, May 2, 2015
  • Time: 11:06 am
  • Venue: Henry B. Gonzalez Convention Gonzalez Convention Center, San Antonio, TX

About Macrocure Ltd.

Macrocure Ltd. is a clinical-stage biotechnology company focused on developing a novel therapeutic platform to address chronic and hard-to-heal wounds, such as DFUs and VLUs. The Company's novel approach is to treat and close chronic and other hard-to-heal wounds by injecting the human body's own wound healing and regenerative components directly into the wound itself.

About CureXcell

Macrocure's lead product candidate, CureXcell, is a unique combination of living human white blood cells that have been activated to facilitate the healing process and stimulate wound closure. CureXcell addresses each phase of healing in the impaired wound, including the production of growth factors and other biochemical factors involved in fibroblast activation, cell migration and extracellular matrix production, stimulating the body's natural healing process. CureXcell is currently in two pivotal, Phase III, double-blind clinical trials targeting a broad indication for the treatment of all types of wounds below the knee. For more information, please visit: www.macrocure.com.

Cautionary Note Regarding Forward-Looking Statements

This press release includes forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, Section 21E of the US Securities Exchange Act of 1934, as amended, and the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts, such as statements regarding assumptions and results related to financial results forecasts, commercial results, clinical trials and regulatory authorizations. Forward-looking statements are based on Macrocure's current knowledge and its present beliefs and expectations regarding possible future events and are subject to risks, uncertainties and assumptions. Actual results and the timing of events could differ materially from those anticipated in these forward-looking statements as a result of several factors including, but not limited to, unexpected results of clinical trials, delays or denial in regulatory approval process or additional competition in the market, including those risks discussed under the heading "Risk Factors" in Macrocure's Registration Statement on Form F-1 filed with the Securities and Exchange Commission. The forward-looking statements made herein speak only as of the date of this announcement and Macrocure undertakes no obligation to update publicly such forward-looking statements to reflect subsequent events or circumstances, except as otherwise required by law.

CONTACT: Francesca M. DeMartino Investor Relations & Corporate Communications Macrocure Ltd. (310) 739-6476; francesca@macrocure.com

Source:Macrocure